Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
See Anoro Ellipta’s head-to-head data
Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA²⁻⁵ and vs. two LAMA/LABAs.⁶ ⁷
This is a fictional patient for illustrative purposes.
Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1
Who might benefit from Anoro Ellipta?
Meet Robert
He is a 62-year-old COPD patient being treated with a short-acting bronchodilator agonist therapy (SABA) as required, but is not yet on a maintenance therapy.
Symptoms:
- Breathlessness
- Reduction of usual daily activities
- No features suggestive of asthma or steroid responsiveness
Robert is starting to struggle with climbing stairs and doing household chores. He now watches television instead of going for long walks outside, or dancing with his wife.
Fictional patient for illustrative purposes
You might also be interested in…
References
- Anoro Ellipta SmPC
- Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
- GSK data on file RF/UCV/0112/15
- Maleki-Yazdi MR et al. Respir Med 2014;108:1752–1760
- Decramer M et al. Lancet Respir Med 2014;2:472–486.
- Feldman G.J et al. Adv Ther 2017; 34:2518–2533
- Maltais F et al. Adv Ther 2019; 36(9):2434-2449
- Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016;11:719–730.
- Laine DI. Exp Rev Clin Pharmacol 2010;3:43–53.
- Laine DI. J Med Chem 2009;52:2493–2505.
- Slack RJ et al. J Pharmacol Exp Ther 2013;344:218–230
- Hanania N et al. Chest 2012;142:119–127.
- Kempsford R et al. Pulm Pharmacol Ther 2013;26(2):256–264.
- van der Palen J et al. NPJ Prim Care Respir Med 2016;26:16079.
- Svedsater H et al. BMC Pulm Med 2013;13:72–86.
- Riley JH et al. Int J Chron Obstruct Pulm Dis 2016;11:1873–1880.
- Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013 May 28;346:f3359
Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
© 2021 GSK group of companies or its licensor. ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.
PM-GB-UCV-WCNT-200034 May 2021
